Journal
CELL REPORTS MEDICINE
Volume 1, Issue 7, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.xcrm.2020.100126
Keywords
-
Categories
Funding
- le Ministere de l'Economie et de l'Innovation du Quebec, Programme de soutien aux organismes de recherche et d'innovation
- Fondation du CHUM
- Canada's COVID-19 Immunity Task Force (CITF)
- Canadian Institutes of Health Research (CIHR)
- CIHR foundation [352417]
- NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]
- NIH [R01 AI122953-05]
- Tier II Canada Research Chair in Molecular Virology and Antiviral Therapeutics
- Ontario's Early Researcher Award
- CIHR
- MITACS Acceleration postdoctoral fellowship
- CIHR New Investigator Award
- Ontario Early Researcher Award
- CIHR COVID Rapid Response Funding
- W. Garfield Weston Foundation Weston Family Microbiome Initiative
- Canada Research Chair on Retroviral Entry [RCHS0235 950-232424]
Ask authors/readers for more resources
SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available